N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide
C23H20ClF3N4O2 — CID 112836032
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide
N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide (PubChem CID 112836032) has the molecular formula C23H20ClF3N4O2 and a molecular weight of 476.89 g/mol. Its IUPAC name is N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide.
Molecular Properties
| Compound Name | N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide |
|---|---|
| PubChem CID | 112836032 |
| Molecular Formula | C23H20ClF3N4O2 |
| Molecular Weight | 476.89 g/mol |
| Exact Mass | 476.12 |
| IUPAC Name | N-[2-chloro-5-(propanoylamino)phenyl]-5-cyclopropyl-1-[3-(trifluoromethyl)phenyl]pyrazole-4-carboxamide |
| SMILES | CCC(=O)Nc1ccc(Cl)c(NC(=O)c2cnn(-c3cccc(C(F)(F)F)c3)c2C2CC2)c1 |
| InChI | InChI=1S/C23H20ClF3N4O2/c1-2-20(32)29-15-8-9-18(24)19(11-15)30-22(33)17-12-28-31(21(17)13-6-7-13)16-5-3-4-14(10-16)23(25,26)27/h3-5,8-13H,2,6-7H2,1H3,(H,29,32)(H,30,33) |
| InChIKey | BOMFSRLYUVIXQV-UHFFFAOYSA-N |
| XLogP | 6.02 |
| TPSA | 76.02 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 476.89 |
| LogP ≤ 5 | 6.02 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 112836032 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.